John McManus - Aeolus Pharmaceuticl CEO and Pres
AOLS Stock | USD 0.0001 0.00 0.00% |
CEO
Mr. John L. McManus is President, Chief Executive Officer of Aeolus Pharmaceuticals Inc. Mr. McManus began as a consultant to Aeolus in June 2005 as President. He became employed as our President and Chief Operating Officer in July 2006 and was appointed President and Chief Executive Officer in March 2007. Mr. McManus, who received his degree in business administration from the University of Southern California in 1986, is the founder and president of McManus Financial Consultants, Inc., which provides strategic, financial and investor relations advice to senior managements and boards of directors of public companies, including advice on mergers and acquisitions. These companies have a combined value of over 25 billion. He has served as president of MFC since 1997. In addition, Mr. McManus previously served as Vice President, Finance and Strategic Planning to Spectrum Pharmaceuticals, Inc., where he had primary responsibility for restructuring Spectrums operations and finances, including the design of strategic and financial plans to enhance Spectrums corporate focus, and leading the successful implementation of these plans and relisting of the Company on NASDAQ. The implementation of these plans led to an increase in Spectrums market value from 1 million to more than 125 million at the time of Mr. McManus departure. since 2011.
Age | 59 |
Tenure | 13 years |
Phone | 949-481-9825 |
Web | https://www.aeoluspharma.com |
Aeolus Pharmaceuticl Management Efficiency
The company has return on total asset (ROA) of (0.903) % which means that it has lost $0.903 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8643) %, meaning that it created substantial loss on money invested by shareholders. Aeolus Pharmaceuticl's management efficiency ratios could be used to measure how well Aeolus Pharmaceuticl manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 5 records | CEO Age | ||
Hermann Luebbert | Biofrontera | 68 | |
Isao Teshirogi | Shionogi Co | 64 | |
Richard Nanula | Lucy Scientific Discovery | 63 | |
Frank Lee | Pacira Pharmaceuticals | 56 | |
James Hall | Lifecore Biomedical | 61 |
Management Performance
Return On Equity | -1.86 | |||
Return On Asset | -0.9 |
Aeolus Pharmaceuticl Leadership Team
Elected by the shareholders, the Aeolus Pharmaceuticl's board of directors comprises two types of representatives: Aeolus Pharmaceuticl inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aeolus. The board's role is to monitor Aeolus Pharmaceuticl's management team and ensure that shareholders' interests are well served. Aeolus Pharmaceuticl's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aeolus Pharmaceuticl's outside directors are responsible for providing unbiased perspectives on the board's policies.
Chris Rallis, Independent Director | ||
Amit Kumar, Independent Director | ||
David Cavalier, Chairman of The Board, CFO and Secretary | ||
Christopher Stanley, VP Operations | ||
John Farah, Independent Director | ||
John Clerici, Director | ||
John McManus, CEO and Pres | ||
Mitchell Kaye, Director | ||
Jeffrey Scott, Director |
Aeolus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Aeolus Pharmaceuticl a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -1.86 | |||
Return On Asset | -0.9 | |||
Operating Margin | (5.31) % | |||
Current Valuation | 167.29 K | |||
Shares Outstanding | 152.09 M | |||
Price To Earning | (2.37) X | |||
Price To Book | 0.81 X | |||
Price To Sales | 0.22 X | |||
Revenue | 2.08 M | |||
Gross Profit | (805 K) |
Pair Trading with Aeolus Pharmaceuticl
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aeolus Pharmaceuticl position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aeolus Pharmaceuticl will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Aeolus Pharmaceuticl could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aeolus Pharmaceuticl when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aeolus Pharmaceuticl - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aeolus Pharmaceuticl to buy it.
The correlation of Aeolus Pharmaceuticl is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aeolus Pharmaceuticl moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aeolus Pharmaceuticl moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aeolus Pharmaceuticl can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aeolus Pharmaceuticl. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Aeolus Pink Sheet analysis
When running Aeolus Pharmaceuticl's price analysis, check to measure Aeolus Pharmaceuticl's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aeolus Pharmaceuticl is operating at the current time. Most of Aeolus Pharmaceuticl's value examination focuses on studying past and present price action to predict the probability of Aeolus Pharmaceuticl's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aeolus Pharmaceuticl's price. Additionally, you may evaluate how the addition of Aeolus Pharmaceuticl to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
CEOs Directory Screen CEOs from public companies around the world |